Table 4.
Effects of pharmacotherapy for PTSD prevention in child and adolescent participant RCTs.
| Pharmacotherapy | Outcome | Comparisons | Participants (n) | RR/SMD (95% CI) | I2 | GRADE judgement |
|---|---|---|---|---|---|---|
| Propranolol | PTSD severity 1–3 months | 1 | 20 | SMD: 0.01 (−0.87 to 0.89) | NA | Very low |
| Propranolol | PTSD 1 month–7 years | 2 | 217 | RR: 0.48 (0.13 to 1.77) | NA | Very low |
| Imipramine (vs. chloral hydrate) | ASD severity 0–7 days | 1 | 25 | RR: 2.17 (1.04 to 4.51) | NA | Very low |
PTSD, post-traumatic stress disorder, ASD, acute stress disorder, n, number of participants included at final assessment, RR, relative risk,
SMD, standard mean difference, CI, confidence interval, NA, not applicable